ErVimmune Partners with Servier to Identify Regulatory Mechanisms of Endogenous Retroviruses in Tumors

On October 11, 2023 ErVaccine Technologies (now ErVimmune), a French biotechnology company developing therapeutic vaccines and cellular immunotherapies targeting unconventional tumor antigens, reported a sponsored research agreement with Servier that will leverage ErVimmune’s expertise and proprietary platforms to discover biomarkers of response to therapies under development by Servier (Press release, ErVaccine, OCT 11, 2023, View Source [SID1234635852]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are delighted to have established a research collaboration with Servier who has a proven track record in oncology," said Stéphane Depil, MD, PhD, founder and Executive Chairman of ErVimmune. "Together we will evaluate the impact of modulating a new cancer target on the expression of specific endogenous retroviruses with the aim of discovering novel therapeutic approaches in the field of cancer immunotherapy. Servier, with their deep and integrated capabilities throughout the entire pharmaceutical R&D chain, is an ideal partner for ErVimmune in this development."

"ErVimmune has a unique platform for the identification and validation of unconventional tumor epitopes. The strong synergies between the Servier research team and ErVimmune’s expertise will allow us to exploit new mechanisms for cancer immunotherapies with the potential to change the cancer treatment landscape
as we know it today," said Don Simons, PhD, Head of U.S. Pharmacology at Servier.

Under the terms of the agreement Servier will fund research efforts to discover endogenous retrovirus- derived biomarkers and investigate mechanisms that regulate expression of ErVimmune’s proprietary cancer vaccine targets.